Program Agenda

Thursday, October 20, 2022

2:00 – 9:00 PM REGISTRATION

Friday, October 21, 2022

7:00 AM – 5:00 PM REGISTRATION
8:00 – 8:10 AM OPENING CEREMONY

Mitchell S. Cairo, MD, Chair, USA

8:10 – 9:00 AM ANGELO ROSOLEN, MD MEMORIAL LECTURE
8:10 – 8:15 AM INTRODUCTION

Marta Pillon, MD, Italy, & Lara Mussolin, PhD, Italy

8:15 – 8:20 AM INTRODUCTION FOR CATHERINE PATTE, MD, FRANCE

Laurence Brugieres, MD, France

8:20 – 8:35 AM IN B-CELL LYMPHOMA: SUCCESSFUL COLLABORATION BETWEEN EUROPE AND NORTH AMERICA. WHAT KIND OF PARTNERSHIP WITH AFRICA?

Catherine Patte, MD, France

8:35 – 8:40 AM INTRODUCTION FOR SHERRIE PERKINS, MD, PhD, USA

Megan Lim, MD, PhD, USA

8:40 – 8:55 AM THE ROLE OF PATHOLOGY IN SHAPING TREATMENT FOR PEDIATRIC NHL: A 25 YEAR PERSPECTIVE

Sherrie Perkins, MD, PhD, USA

9:00 – 10:45 AM PLENARY SESSION I – MATURE B-CELL NHL

Moderators: Stanton Goldman, MD, USA & Veronique Minard-Colin, MD, PhD, France

9:00 – 9:20 AM RITUXIMAB IMPROVES OUTCOME IN CHILDREN AND ADOLESCENTS WITH ADVANCE STAGE MATURE B-NHL

Veronique Minard-Colin, MD, PhD, France

9:20 – 9:40 AM RITUXIMAB LOWERS THE CHEMOTHERAPY BURDEN IN CHILDREN AND ADOLESCENTS WITH LIMITED STAGE MATURE B-NHL

Stanton Goldman, MD, USA

9:40 – 10:00 AM MUTATIONAL LANDSCAPE IN PEDIATRIC BURKITT-LIKE LYMPHOMA (BLL) WITH 11q ABERRATION

Reiner Siebert, MD, Germany

10:00 – 10:10 AM Non-Germinal Center B-cell Subtype of Pediatric Diffuse Large B-Cell Lymphoma in Japan: A Multi-Case Analysis

D. Hori1,2, R. Kobayashi1,2, A. Nakazawa1,3, H. Iwafuchi1,4, W. Klapper5, t. Osumi1,6, N. Fujita1,7, T. Mitsui1,8, Y. Koga1,9, T. Mori1,10, R. Fukano1,11, K. Ohki1,12, M. Kamei1,13, T. Mori1,14, M. Tanaka1,15, T. Tsuchimochi1,16, K. Moriya1,17, K. Tao1,18, A. Kada19, M. Sekimizu1,20

10:10 – 10:20 AM BCR Expression in Burkitt Lymphoma: New Insight in Mutational Landscape

M. Siciliano1, M. Vannucchi1, S. Tornambè1, M. Granai2, F. Arcuri1, E. Sorrentino1, V. Mancini1, N. de Leone1, S. Lazzi1, R. Siebert3, L. Leoncini1, C. Bellan*1

10:20 – 10:30 AM Noncoding RNAs in Burkitt Lymphoma

C. López1,2,3, H. Kretzmer4,5,6,7, E. Chteinberg1, S. H Bernhart4,5,6, S. Glaser1, P. Patil1, O. Ammerpohl1, ICGC MMML-Seq Consortium, B. Burkhardt8, M. Schlesner9,10, S. Hoffmann4,5,6,11, R. Siebert1,2

10:30 – 10:45 AM PANEL DISCUSSION AND QUESTIONS & ANSWERS
10:45 – 11:00 AM COFFEE BREAK
11:00 – 12:45 PM PLENARY SESSION II – LYMPHOMA TRANSLATIONAL BIOLOGY (DEDICATED IN MEMORY TO WARREN SANGER, PhD)

Moderators: Lara Mussolin, PhD, Italy & Wolfram Klapper, MD, Germany

11:00 – 11:20 AM PRECISION MEDICINE IN ADULT LYMPHOMA

Keynote Speaker # 1– Louis Staudt, MD, PhD, USA

11:20 – 11:40 AM EMERGING EPIGENETIC MODULATING THERAPIES IN NHL

Ari Melnick, MD, USA

11:40 – 12:00 PM INTEGRATIVE GENOMIC ANALYSIS OF PEDIATRIC T-LYMPHOBLASTIC LYMPHOMA

Birgit Burkhardt, MD, PhD, Germany

12:00 – 12:10 PM ALK+ ALCL Evades Immune Surveillance through NPM-ALK-Driven Epigenetic Repression CD48

R. Wu1, A. Sahasrabuddhe1, E. Ivan2, T. Shaw3, C. Mullighan4; V. Leventaki4, K. Elenitoba-Johnson1, M. Lim1

12:10 – 12:20 PM Burkitt Lymphoma and High-Grade B-Cell Lymphoma with 11q Aberrations Share a Transcriptional Profile Resembling a Subpopulation of Early Dark Zone Cells 

Gioia Di Stefano1,2,3*, Emil Chteinberg3*, Henry Loeffler-Wirth4, Sina Hillebrecht3, Rabea Wagener3, Dmitriy Abramov5, Birgit Burkhardt6, Abner Louissant7, Heike Horn13, Anja Mottok3,8, Ilske Oschlies9, Wolfram Klapper9, Kristian Schafernak10, Yanming Zhang11, Coral Del-Val3,12, Andreas Rosenwald8, Hans Binder4, German Ott13, Lorenzo Leoncini2, Reiner Siebert3

12:20 – 12:30 PM Burkitt Lymphoma and High-Grade B-Cell Lymphoma with 11q Aberrations Share a Transcriptional Profile Resembling a Subpopulation of Early Dark Zone Cells 

Gioia Di Stefano1,2,3*, Emil Chteinberg3*, Henry Loeffler-Wirth4, Sina Hillebrecht3, Rabea Wagener3, Dmitriy Abramov5, Birgit Burkhardt6, Abner Louissant7, Heike Horn13, Anja Mottok3,8, Ilske Oschlies9, Wolfram Klapper9, Kristian Schafernak10, Yanming Zhang11, Coral Del-Val3,12, Andreas Rosenwald8, Hans Binder4, German Ott13, Lorenzo Leoncini2, Reiner Siebert3

12:30 – 1:00 PM PANEL DISCUSSION AND QUESTIONS & ANSWERS (non-CME event)
1:00 – 1:45 PM LUNCH SYMPOSIUM – The ALLternative: Confronting ALL With ASPARLAS As Part Of A Multi-Agent Chemotherapy Regimen – Supported by Servier Pharmaceuticals
2:15 – 4:15 PM PLENARY SESSION III – RARE NON-HODGKIN LYMPHOMA

Moderators – Ana Xavier, MD, USA & Yonghong Zhang, MD, PhD, China

2:15 – 2:35 PM NEW THERAPEUTIC APPROACHES TO ADVANCED NK/T-CELL LYMPHOMA

Ana Xavier, MD, USA

2:35 – 2:55 PM PEDIATRIC-TYPE FOLLICULAR LYMPHOMA (PTFL) and MARGINAL ZONE LYMPHOMA (MZL)

Karin Mellgren, MD, Sweden

2:55 – 3:15 PM EBV, HLH AND THE ASSOCIATED SPECTRUM OF T/NK-CELL LYMPHOPROLIFERATION

Nader El-Mallawany, MD, USA

3:15 – 3:25 PM EBV-Driven Lymphoid Neoplasms Associated with ALL Maintenance Therapy: An International Observational Study

S. Elitzur1, A.Vora2 B. Burkhardt3, H. Inaba4, A. Attarbaschi5, A. Baruchel6, G. Escherich7, B. Gibson8, H. Liu9, M. Loh10, A. Moorman11, A. Moricke12, R. Pieters13, A. Uyttebroeck14, S. Baird15, J. Bartram2, M. Ben-Harosh16, Y. Bertrand17, T. Buitenkamp18, K. Caldwell19, R. Drut20, A. Geerlinks21, J. Grainger22, S. Haouy23, N. Heaney24, M. Huang25, D. Ingham26, Z. Krenova27, M. Kuhlen28, T. Lehrnbecher29, A. Manabe30, F. Niggli31, C. Paris32, S. Revel-Vilk33, P. Rohrlich34, B. Sandeep35, M. Sinno36, T. Szczepanski37, M. Tamesberger38, R. Warrier39, M. Wolfl40, R. Nirel41, S. Izraeli1, A. Borkhardt42, K. Schmiegelow43

3:25 – 3:35 PM The Challenge of Prospective Distinction Between Non-Neoplastic Versus Neoplastic EBV-Associated HLH

N. Gulati,1,2 O. Eckstein,1,2 J. Agrusa,1,2 K. Kamdar,1,2 R. Rouce,1,2 C. Curry,3,4 K. Fisher,3,4 L. Forbes,3,5 A. Grim,2,6 E. Peckham-Gregory,1,2,7 K. McClain,1,2 C. Allen,1,2 N. El-Mallawany1,2

3:35 – 3:45 PM Survival of Patients with Extranodal NK-cell Lymphoma in the United States

A. Xavier1, N. El-Mallawany2, M. Ehrhardt3, L. Costa MD4, M. Cairo5,6,7,8,9

3:55 – 4:15 PM PANEL DISCUSSION AND QUESTIONS & ANSWERS
4:15 – 4:30 PM COFFEE BREAK
4:30 – 6:15 PM PLENARY SESSION IV – IMMUNOLOGY, CELL THERAPY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION

Moderators: Amos Burke, MD, UK & Wilhelm Woessmann, MD, Germany

4:30 – 4:50 PM PAST, PRESENT AND FUTURE OF CAR T-CELLS

Keynote Speaker #2 – Carl June, MD, USA

4:50 – 5:10 PM IMMUNE RESPONSE TO ALK IN ALK-POSITIVE LYMPHOMAS

Wilhelm Woessmann, MD, Germany

5:10 – 5:30 PM NOVEL IMMUNOTHERAPEUTICS

Mitchell S. Cairo, MD, USA

5:30 – 5:40 PM CD72 Nanobody CAR-T Cells Have Potent Antitumor Efficacy in B Cell Malignancies

W.Temple1, M. Nix2, G. Wicaksono2, D. Wang3, P. Phojanakong3, V. Steri3, B. Hann3, M. Hermiston1, A. Wiita2

5:40 – 5:50 PM Impact of Rituximab on Immune Status Following Therapy in Children and Adolescents with High-Risk Mature B-Cell Non-Hodgkin Lymphoma: Results of the Inter-B-NHL Ritux 2010 Trial

S. Alexander1, A. Aupérin2, S. Bomken3, M. Csoka4, B. Kazanowska5, A. Chiang6, M. Andrés Moreno 7, A. Uyttebroeck8, A. Burke9, J. Zsiros10, M. Pillon11, C. Bollard12, D. Barkauskas13, K. Wheatley14, C. Patte15, T. Gross16, V. Minard-Colin1

5:50 – 6:00 PM EPSTEIN-BARR Virus Orchestrate the Tumor Microenvironment of Burkitt Lymphoma

M. Siciliano1, S. Tornambè1, M. Del Corvo2, M. Granai3, L. Mundo4, M. Sapienza2, F. Arcuri1, V. Mancini1, R. Santi5, G. Di Stefano5, T. Marafioti6, G. Ott7, R. Siebert8, L. Quintanilla Fend3, F. Fend3, S. Pileri2, L. Leoncini*1, S. Lazzi1

6:00 – 6:15 PM PANEL DISCUSSION AND QUESTIONS & ANSWERS
6:15 – 7:45 PM WELCOME RECEPTION & POSTER VEIWING (ALL REGISTRANTS)

Saturday, October 22, 2022

 

7:00 AM – 5:00 PM REGISTRATION
7:00 – 7:45 AM BREAKFAST SYMPOSIUM –Understanding Tumor Lysis Syndrome Associated with Hyperuricemia in an Evolving Pediatric Cancer Treatment Landscape, Mitchell S. Cairo, MD, USA – Supported by Sanofi
7:45 – 8:30 AM MEET THE PROFESSORS (Choose One Session)(non-CME event)
Session 1 ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): THE EUROPEAN PERSPECTIVE

Laurence Brugieres, MD, France

Session 2 NK/T CELL LYMPHOMAS: THE JAPANESE PRESPECTIVE

Ritsuro Suzuki, MD, PhD, Japan

Session 3 MINIMAL DISSEMINATED DISEASE AND MINIMAL RESIDUAL DISEASE DETECTION

Christine Damm-Welk, PhD, Germany

Session 4 MOLECULAR-BASED THERAPEUTIC APPROACHES TO LANGERHANS CELL HISTIOCYTOSIS

Carl Allen, MD, PhD, USA

8:30 – 10:15 AM PLENARY SESSION V – ADOLESCENT AND YOUNG ADULT HODGKIN AND NON-HODGKIN LYMPHOMA

Moderators – Owen Smith, MA, MB, Ireland & Michael Link, MD, USA

8:30 – 8:50 AM OUTCOME OF AYA vs CHILDHOOD NHL: THE IRISH EXPERIENCE

Owen Smith, MA, MB, Ireland

8:50 – 9:10 AM OUTCOME OF AYA PATIENTS WITH MATURE B-CELL LYMPHOMA TREATED ON PEDIATRIC INSPIRED PROTOCOLS

Sarah Alexander, MD, Canada

9:10 – 9:30 AM PATHOBIOLOGY AND NOVEL APPROACHES TO PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBL)

Lisa Giulino-Roth, MD, USA

9:30 – 9:40 AM Childhood and Adolescent Hodgkin Reed-Sternberg Cells Demonstrate Unique Gene Expression Signature Consistent with Oncogenic-Induced Senescence

J. Agrusa1, H. Lin1, H. Abhyankar1, J. Velazquez, E. Fattah1, B. Scull1, N. Ozuah1, O. Eckstein1, N. El-Mallawany1, N. Gulati1, J. Lubega1, T. Horton1, K. Kamdar1, K. McClain1, C. Man1, C. Allen1.

9:40 – 9:50 AM Excellent Outcome of Children/Adolescents with Primary Mediastinal Large B Cell Lymphoma Treated with LMB-Based Chemotherapy with Rituximab

M. Dourthe1,2 , A. Phulpin 3 , A. Auperin4, M. Couec 5, P. Dartigues6, S. Ducassou7, N. Garnier8 , S. Haouy9, T. Leblanc1, A. Lambilliotte10, A. Leruste11, A. Jourdain12, A. Spiegel13, C. Rigaud14, M. Simonin15, J. Bonneau16, A. Verschuur17, G. Plat18, M. Poirée19, N. Buchbinder20, J. Landman-Parker15, C. Patte14, v. Minard-Colin 14,21

9:50 – 10:00 AM Reducing the Burden of Oncology Chemoradiotherapy And Radiation Exposure from Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults with Lymphoma (RADICAL, Hodgkin Lymphoma Cohort).

J. Hochberg1*, A. Xavier2, A. Audino3, M. Barth4, R. Miles5, S. Kahwash6, S. Voss7, S. Braniecki3, C. Moorthy8, S. Armenian9, M. Ehrhardt10, M. Lim11, L. Harrison1, S. Goldman12, M. Cairo1,13,14,15,16

10:00 – 10:15 AM PANEL DISCUSSION AND QUESTIONS & ANSWERS
10:15 – 10:30 AM COFFEE BREAK
10:30 – 12:30 PM PLENARY SESSION VI – SURVIVORSHIP AND LATE EFFECTS

Moderators – Matthew Ehrhardt, MD, USA & Jessica Hochberg, MD, USA

10:30 – 10:50 AM LATE HEALTH OUTCOMES IN CHILDREN AND ADOLESCENTS WITH MATURE B-CELL NHL

Matthew Ehrhardt, MD, USA

10:50 – 11:10 AM SECOND MALIGNANCY AFTER TREATMENT IN CHILDREN AND ADOLESCENTS WITH NHL

Marta Pillon, MD, Italy

11:10 – 11:30 AM FERTILITY AND SEXUALITY IN CHILDHOOD AND ADOLESCENT NHL SURVIVORS

TBD

11:30 – 11:40 AM Long Term Pulmonary and Cardiac Function Affection among Non-Hodgkin’s Lymphoma Survivors

A. Ayad1, A. Hamoda1, 2, R. Khedr1, 2, N. Elnabarawy3, E. Rifky3, T. Diab4, L. Leihmann 5, A. El-Haddad

11:40 – 12:10 PM PANEL DISCUSSION AND QUESTIONS & ANSWERS (non-CME event)
12:15 – 12:30 PM PICK UP LUNCH
12:30 – 1:15 PM LUNCH SYMPOSIUM –The Only Recombinant ERWINIA ASPARAGINASE Approved for the T Treatment of ALL/LBL, Scott Howard, MD, MSc -Supported by Jazz Pharmaceuticals
1:45 – 3:45 PM PLENARY SESSION VII – NOVEL THERAPEUTICS

Moderators – Lara Mussolin, PhD, Italy & Carl Allen, MD, PhD, USA

1:45 – 2:05 PM ALK INHIBITOR THERAPY IN ALCL

Masahiro Sekimizu, MD, Japan

2:05 – 2:25 PM TARGETING THE P13K/AKT/MTOR PATHWAY

Matthew Barth, MD, USA

2:25 – 2:45 PM EXOSOMES IN NHL OF CHILDHOOD: SMALL VESICLES WITH A GREAT POWER

Lara Mussolin, PhD, Italy

2:45 – 2:55 PM Obinutuzumab (GA101) vs. Rituximab Significantly Enhances Cell Death, Antibody-Dependent Cytotoxicity and Improves Overall Survival Against CD20+ Primary Mediastinal B-Cell Lymphoma (PMBL) in a Xenograft NOD-Scid IL2Rgnull (NSG) Mouse Model: A Potential Targeted Agent in the Treatment of PMBL

Y. Chu1, A. Awasthi1, S. Lee1,2, D. Edani1, C. Yin1, J. Hochberg1, T. Shah1, T. Chung6, J. Ayello1, C. van de Ven1, C. Klein7, D. Lee8, M. Cairo1,2,3,4,5,

2:55 – 3:05 PM Resistance to Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) in Paediatric Anaplastic Large Cell Lymphoma (ALCL)

L. Hare1,2, N. Prokoph1, A. Burke2*, S. Turner1,3*

3:35 – 3:15 PM Brigatinib Shows Preclinical Promise for Aggressive Relapsed/Refractory AK=LK-Positive ALCL

J. Matthews1*, N. Prokoph1*, R. Trigg1, I. Montes-Mojarro2, F. Fend2, L. Kenner4-7, B. Geoerger8,9, R. Johnston10, M. Murray1,3, L. Brugières8, A. Burke3, Suzanne D Turner1,11,‡

3:15 – 3:25 PM A Novel Cytokine-Antibody Fusion Protein, N-820, to Enhance the Functions of Ex-Vivo Expanded Natural Killer Cells against Burkitt Lymphoma

Y. Chu1*, G. Nayyar1, N. Su1, J. Rosenblum1, P. Soon-Shiong2, J. Lee2, J. Safrit3, M. Barth4, D. Lee5, M. Cairo1,6,7,8,9*

3:25 – 3:45 PM PANEL DISCUSSION AND QUESTIONS & ANSWERS
3:45 – 4:00 PM COFFEE BREAK
4:00 – 6:00 PM PLENARY SESSION VIII – POSTER DISCUSSION

Moderators – Paul Galardy, MD, USA; Birgit Burkhardt, MD, PhD, Germany; Laurence Brugieres, MD, France; & Itziar Salaverria, PhD, Spain

WORLD WIDE EXPERIENCES

Discussant: Itzar Salverria, PhD

Mature B Cell Non-Hodgkin Lymphoma Treatment and Results in a Retrospective Cohort of Children and Adolescents Treated Between 2016 and 2020 in Latin

G. Chantada1-2, M. Schelotto1, A. Braz3, M. Soria4, F. Luisi5, C. Salgado6, C. Montilva7, C. Garrido8, P. Rezende9, D. Flores1, P. Domínguez10, A. Peña10, M. Metzger2

18F-FDG-PET/CT in the Assessment of Bone Marrow Involvement in Pediatric Non-Hodgkin Lymphoma-A Single Center Experience

M. Siri1, H. Rosenfeld-Keidar1, M. Yaffe-Ornstein1, R. Shukrun1, R. Elhasid1

Pediatric Low Grade Lymphoma: A Report from A Single

N.Kurucu1, T. Kutluk1, A. Sağlam2, B. Oğuz3, M. Haliloğlu3, B. Aydın1, B. Yalçın1, A. Varan1, A. Üner2

Summary of the Mid-Term efficacy of China Net Children Lymphoma (CNCL) -Mature B-Cell Lymphoma-2017 Regimen in the Treatment of Pediatric Burkitt’s Lymphoma

Z. Meng1

B-cell NHL Relapses in PPLLSG Patients in Years 2004-2021

E. Latos-Grażyńska1, D. Przystupski1, B. Kazanowska1

Clinical Spectrum of Precursor B-Cell Lymphoblastic Malignancies: A Large Cohort Study of 364 Pediatric Patients

E. Kroeze1, M. Bakker1, J. Boer1, M. Hagleitner, B. Burkhardt2, L. Padilla2, T. Mori3, A. Attarbaschi4, J. Verdú-Amorós5, M. Pillon6, L. Anderzhanova7, E. Kabíčková8, A. Chiang9, R. Kebudi10, K. Mellgren11, J. Lasic12, J. Jazbec13, J. Meijerink1, A. Beishuizen1,14, J. Loeffen1, on behalf of the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group.

LYMPHOMA BIOLOGY

Discussant: Paul Galardy, MD

Genome-Wide Genomic Abnormalities and Functional Essential Genes in Burkitt

Lymphoma: A Systematic Review and Meta-Analysis

P. Zhou1,2,3, M. Zaka1,2,3, A. Newman1,2,3, A. Blain3, N.Hajduga1,2, S. Bomken3,4, C. Bacon3,5, V. Rand1,2,3*

Characterization of IG-MYC-Breakpoints and their Application for Quantitative Minimal Disease Monitoring in High-Risk Pediatric Burkitt-Lymphoma and –Leukemia

C. Damm-Welk1, P. Möker1, U. Stadt2, M. Zimmermann3, M. Alawi4, S. Mueller5, J. Finger5, F. Knörr1,6, A. Riquelme1, I. Oschlies7, W. Klapper7, J. Bradtke8, B. Burkhardt5, W. Woessmann1

Single-cell Transcriptomic Analysis of Pediatric Burkitt Lymphoma Reveals Intra-Tumor Heterogeneity

C. Corinaldesi1,*, I. Gallingani2,3*, A. Holmes1, F. Lovisa2,3, E. Carraro2, M. Pillon2, R. Dalla-Favera1,4,5, K. Basso1,4, L. Mussolin2,3.

Blocking the BCL10-MALT1 Interaction in Diffuse B-Cell Lymphoma

L. Maurer1, H. Kang1, M. Smyers1, L. Klei1 J. Cheng1, M. Trotta1, D. Hu1, P. Ekambaram1, M. Murai2, Z. Nikolovska-Coleska2, B. Chen1, P. Lucas1, L. McAllister-Lucas1

Rituximab Clearance in Pediatric Patients with Mature Aggressive B-Cell Non-Hodgkin Lymphoma

I. Tölle1, C. Lanvers-Kaminsky1, M. Bethke1, G. Randau1, M. Rolfing1, A. Tann1, M. te Vrugt1, K. Mellgren2, S. Müller1, B. Burkhardt1

Immunology, Cell therapy, HSCT

Discussant: Birgit Burkhardt, MD, PhD

Safety Profile of Rituximab in Initial Treatment of Children and Adolescents with Mature Aggressive B-NHL

J. Finger1, R. Schmidt2, K. Mellgren3, M. Gunnes4, P. Huttunen5, E. Kabíčková6, A. Attarbaschi7, F. Ceppi8, P. Wehner9, S. Müller1, B. Burkhardt1

Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients with B-Cell Non-Hodgkin Lymphoma

A. Gardenswartz1, K. Seiter4, J. Hochberg1, E. Morris1, L. Harrison1, Y. Chu1, J. Basso1, P. Gerard2, H. Islam3, J. Ayello1, M. Cairo1,2,3,4,5,6*

1Department of Pediatrics, New York Medical College, Valhalla, NY, USA; 2Department of Radiology, New York Medical College, Valhalla, NY, USA; 3Department of Pathology, New York Medical College, Valhalla, NY, USA; 4Department of Medicine, New York Medical College, Valhalla, NY, USA; 5Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA; 6Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA

Combined Bortezomib and Venetoclax Targets the Pro-Survival Functions of Latent Viral Proteins in Epstein-Barr Virus-Driven Lymphoproliferative Diseases

A. Chiang1, K. Tam1, R. Au-Yeung2

A Multicenter Pilot Study Using Induction Chemo-Immunotherapy Followed by Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell

Advanced Stage Mature Non-Anaplastic T/NK-cell lymphoma/leukemia in Children, Adolescent, and Young Adults (CAYA)

A. Xavier1*; L. Harrison2; R. Miles3; S. Voss4; M. Lim5; M.Cairo2,6,7,8,9

PTLD

Discussant: Thomas Gross, MD, PhD

Outcome of Children Treated for Recurrent Epstein-Barr virus (EBV)-associated Post- Transplant Lymphoproliferative Disease (PTLD)

K. Devine1, A. Seif1, B. Laskin1, A. Reilly1

Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation

V. Vergote1, A. Uyttebroeck2, C. Deroose3, S. Fieuws4, W. Laleman5, B. SPRANGERS6, J. Van Cleemput7, G. Verhoef1, R.Vos8, T. Tousseyn9,1, D. Dierickx1,10

Post-Transplant Lymphoproliferative Syndrome in Children and Adolescents Undergoing Transplants Hepatic and Renal: Epidemiological, Diagnostic and Therapy in a Brazilian Center

F. Luisi1,2, C. Matiuzzi2, S. Martins3, N. da Silva Santos1,2, T. Barlera1,2, A. de Sousa 1,2, S. Abib1,2, H. Lederman1,2, M. Alves1,2

NOVEL THERAPEUTICS/ALCL

Discussant: Laurence Brugieres, MD

Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell- Mediated Cytotoxicity Combined With anti-CD20 or anti-CD79 therapeutic antibodies and NKTR-255 in Burkitt Lymphoma (BL)

Y. Chu1*, M. Tian1*, M. Marcondes2, W. Overwijk2, D. Lee3, C. Klein4, M. Cairo1,5,6,7

Immunoglobulin Subclasses of Anti-ALK Antibodies in Pediatric Anaplastic Large Cell Lymphoma

F. Knörr1,2*, L. Sabra1*, W. Wößmann1, C. Damm-Welk1

Variant ALK-Fusion Positive Anaplastic Large Cell Lymphoma (ALCL): A Population-Based Cohort of the NHL-BFM Study Group

C. Damm-Welk1, J. Luedersen1, U. Stadt2, J. Richter3, I. Oschlies3, W. Klapper3, A. Rosenwald4, M. Kalinova5, I. Simonitsch-Klupp6, R. Siebert7, M. Zimmermann8, M. Alawi9, J. Nakel10, K. Scheinemann11, F. Knörr1, 12, A. Attarbaschi13, E. Kabickova14, W. Woessmann1

Inhibition of N6-Methyladenosine (m6A) Modification as a Novel Treatment Strategy for ALK-Positive Anaplastic Large Cell Lymphoma (ALCL)

L. Mun1, V. Miano1, N. Webster2, B. Andrews2, N. Han3, A. Burke4, I. Barberi1*, S. Turner1*

UK; 2Storm Therapeutics Ltd, Moneta Building, Babraham Research Campus, Cambridge, UK; Milner Therapeutics Institute, University of Cambridge, UK;

Pediatric and Young Adult ALK-Negative Anaplastic Large Cell Lymphoma Genetically Differs from the Adult Counterpart

J. Salmeron-Villalobos1,2*, E. James3*, O. Balagué4, S. Mato1,2, N. Garcia1, M. Andres5; A. Attarbaschi6, C. Bacon7; A. Burke8; B. Lockhart9, L. Mussolin10, S. Pervez11; V. Pillai9, I. Simonitsch-Klupp12, M. Veening13, J. Verdu14; G. Wrobel15, I. Salaverria1*, S. Turner3*

Sunday, October 23, 2022

7:00 AM – 1:00 PM REGISTRATION
7:00 – 7:45 AM BREAKFAST SYMPOSIUM – TBD
7:45 – 8:30 AM MEET THE PROFESSORS (CHOOSE ONE SESSION)
Session 1 HEMATOPATHOLGY: WHAT’S NEW IN 2022

Rodney Miles, MD, PhD, USA

Session 2 MENTORING YOUNG INVESTIGATORS IN CHILDHOOD AND ADOLESCENT NHL: THE COG EXPERIENCE

Birte Wistinghausen, MD, USA

Session 3 CLINICAL/PATHOLOGICAL SPECTRUM OF PRIMARY CUTANEOUS LYMPHOMA

Ilske Oschlies, MD, Germany

Session 4 POST-TRANSPLANT LYMPHOFERATIVE DISORDER (PTLD)

Thomas Gross, MD, PhD, USA

8:30 – 10:00 AM PLENARY SESSION IX – BEST ORAL ABSTRACTS IN CHILDHOOD, ADOLESCENT AND YOUNG ADULT NHL

Moderators – Mitchell S. Cairo, MD, USA, Catherine Patte, MD, France & Sherrie Perkins, MD, PhD, USA

8:30 – 8:45 AM The Profiling of Circulating Tumor DNA in Pediatric Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Multicenter, Prospective Clinical Study

J. Wang1, H. Guo2, Y. Cai3, H. Chen3, L. Yang4, H. Dou5, X. Tian6, H. Xiong7, X. Hong8, C. Liang8, Z. Zhen1, J. Zhu1, S. Lu1, F. Sun1, J. Huang1, Y. Zhang1

8:45 – 9:00 AM Pediatric Nodal Marginal Zone Lymphoma and Pediatric-Type Follicular Lymphoma Share a Common Molecular Profile

J. Salmeron-Villalobos1,2*, C. Egan3*, V. Borgmann4*, I. Müller4, B. Gonzalez-Farre1,2, J. Ramis-Zaldivar1,2, D. Nann4, O. Balagué1,2, M. Lopez-Guerra1,2, D. Colomer1,2, I. Oschlies5, W. Klapper5, S. Glaser6, Y. Ko7, I. Bonzheim4, R. Siebert6, F. Fend4, S. Pittaluga3, E. Campo1,2, I. Salaverria1,2§, E. Jaffe, L. Quintanilla-Martinez4,8§

9:00 – 9:15 AM Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell Therapy for Pediatric Refractory/Relapsed Burkitt Lymphoma with Secondary Central Nervous System Involvement

Y. Liu1, B. Deng2, B. Hu1,W. Zhang1, Q. Zhu1, Y. Liu1, S. Wang1, P. Zhang1, J. Yang1, Q. Zheng3, X.Yu3, Z. Gao4, C. Zhou5, W. Han6, A. Chang7*, Y. Zhang1*

9:15 – 9:30 AM Phase 2 KEYNOTE-667 Study of Pembrolizumab (Pembro) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Frontline Chemotherapy (Chemo)

L. Vinti1, Stephen Daw2, C. Alvarez3, F. Fagioli4, A. Beishuizen5, G. Michel6, M. Moleti7, M. Cepelova8, A. Thorwarth9, C. Rigaud10, D. de Sabando11, J. Parker12, Y.Zhu13, P. Pillai13, A. Nahar13, C. Mauz-Koerholz14

9:30 – 9:45 AM Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine in CAYA with Mature De-Novo B-NHL

S. Goldman1, M. Barth2, B. Shiramizu3, Q. Shi4, J. Hochberg5, L. Klejmont5, L. Harrison5, J. Basso5, Y. Chu5, H. Islam6, P. Gerard7, M. Agsalda-Garcia3, T. Shieh3, J. Oesterheld8, K. Heym9, I. Kirov10, R. Drachtman11, P. Harker-Murray12, S. Perkins13, R. Miles13, M. Cairo5,6,14,15,16

9:45 – 10:00 AM A Targeted Gene Expression Classifier Identifies Pediatric T-ALL Patients at High Risk for End Induction Minimal Residual Disease Positivity

L. Meyer1, Ritu P. Roy2, B. Huang1, S. Kimura3, Petri Polonen3, C. Delgado-Martin1, T. Vincent4, T. Ryan4, B. Wood5, Y. Liu3, J. Zhang6, C. Mullighan3, T. Horton7, M. Loh8, M. Devidas9, E. Raetz10, R. Hayashi11, S. Winter12, K. Dunsmore13, S. Hunger4, D. Teachey4, M. Hermiston1, Adam B. Olshen2

10:00 – 10:15 AM COFFEE BREAK
10:15 – 12:00 PM PLENARY SESSION X – ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) AND LYMPHOBLASTIC LYMPHOMA (LL)

Moderators – Suzanne Turner, PhD, UK & Michelle Hermiston, MD, PhD, USA

10:15 – 10:35 AM BRENTUXIMAB VEDOTIN IN CHILDHOOD ALCL

Eric Lowe, MD, USA

10:35 – 10:55 AM ALTERATIONS IN SIGNALING PATHWAYS LEADS TO RESISTANCE IN ALCL

Suzanne Turner, PhD, UK

10:55 – 11:15 AM NOVEL TARGETS IN T-LYMPHOBLASTIC LYMPHOMA

David Teachey, MD, USA

11:15 – 11:35 AM INNOVATIVE APPROACHES TO DETECT MDD/MRD IN ANAPLASTIC LARGE CELL LYMPHOMA AND LYMPHOBLASTIC LYMPHOMA

Megan Lim, MD, PhD, USA

11:35 – 11:45 AM Establishing the Optimal Way to Administer Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) in Paediatric Anaplastic Large Cell Lymphoma (ALCL) to Prevent/Delay Resistance Generation

L. Hare1,2, S. Bell1, A. Burke2*, S. Turner1,3*

11:45 – 11:55 AM Transcription and Replication Impairments Driving MYC-induced B and T Cell Lymphoblastic Lymphomas

A. Sinha1, C. Foster1, C. Sansam2, P. Andrade1, K. Foster1, M. Malone-Perez1, H. Harris1, C. Sansam2, J. Frazer1

11:55 – 12:05 PM Molecular Genetics Analysis of B-Cell Precursor Lymphoma in Pediatric and Adolescent Patients Reveals High Frequency of KMT2A Translocations

I. Iaccarino1, R. Au-Yeung2, L. Padilla,3 M. Zimmermann,4 S. Reinke,1 I. Oschlies,1 G. Escherich,5 W. Woessmann,5 B. Burkhardt,3 W. Klapper

12:05 – 12:20 PM PANEL DISCUSSION AND QUESTIONS & ANSWERS
12:20 – 12:30 PM AWARDS SESSION BEST ORAL ABSTRACT, BEST POSTER DISCUSSION ABSTRACT

& BEST POSTER ABSTRACT

 

Award Committee – Stanton Goldman, MD, USA, and Ronit Elhasid, MD, Israel (Vice Chairs) Anthony Audino, MD, USA; M. Tezer Kutluk, MD, PhD, Turkey; and Vikki Rand, PhD, UK

12:30 – 12:45 PM CLOSING REMARKS

Mitchell S. Cairo, MD, Chair, USA